Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.07
-0.26 (-4.88%)
At close: Oct 29, 2024, 4:00 PM
5.04
-0.03 (-0.59%)
After-hours: Oct 29, 2024, 7:27 PM EDT
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $-1.02M in the quarter ending June 30, 2024, a decrease of -101.04%. This brings the company's revenue in the last twelve months to $298.76M, up 55.71% year-over-year. In the year 2023, Amylyx Pharmaceuticals had annual revenue of $380.79M with 1,612.94% growth.
Revenue (ttm)
$298.76M
Revenue Growth
+55.71%
P/S Ratio
1.15
Revenue / Employee
$778,026
Employees
384
Market Cap
345.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
Dec 31, 2019 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Enhabit | 1.04B |
DocGo | 742.84M |
ZimVie | 453.38M |
Viemed Healthcare | 205.70M |
Anika Therapeutics | 166.88M |
Voyager Therapeutics | 143.77M |
Alpha Teknova | 34.94M |
ClearPoint Neuro | 28.07M |
AMLX News
- 12 days ago - Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Business Wire
- 14 days ago - Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - Business Wire
- 26 days ago - Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - PRNewsWire
- 2 months ago - Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration - Business Wire
- 2 months ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results - Business Wire
- 3 months ago - Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 - Business Wire